Qualigen Therapeutics (NASDAQ: QLGN) names Kevin Chen independent director

Rhea-AI Filing Summary

Qualigen Therapeutics, Inc. reported that its Board of Directors appointed Kevin Chen as an independent director, effective September 26, 2025. As of this appointment, he has not yet been assigned to any Board committees. Chen is currently Chief Economist and CIO of Horizon Financial and serves on several public company boards, including CurrenC Group, Australian Oilseeds Investments, Scage Future and Capitan Investment Ltd. His background includes senior investment roles at Credit Agricole/Amundi Asset Management and Morgan Stanley, as well as academic positions at New York University and other institutions.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 09/29/2025 - 06:04 AM Learn about SEC filing dates

FAQ

What did Qualigen Therapeutics (QLGN) disclose in this 8-K filing?

Qualigen Therapeutics disclosed that its Board of Directors appointed Kevin Chen as an independent member of the Board, effective September 26, 2025.

Who is Kevin Chen, the new independent director at Qualigen Therapeutics (QLGN)?

Kevin Chen, age 47, is Chief Economist and CIO of Horizon Financial and serves on multiple public company boards. He previously held senior investment roles at Credit Agricole/Amundi Asset Management and Morgan Stanley and has extensive academic and policy-related affiliations.

When was Kevin Chen appointed to the Qualigen Therapeutics (QLGN) Board?

Kevin Chen was appointed as an independent director to the Qualigen Therapeutics Board on September 26, 2025, with the appointment effective immediately on that date.

Has Kevin Chen been assigned to any Qualigen Therapeutics Board committees?

As of the date of the report, Kevin Chen had not been appointed to any committees of the Qualigen Therapeutics Board of Directors.

What other boards does Kevin Chen serve on besides Qualigen Therapeutics (QLGN)?

Kevin Chen is a board member of CurrenC Group, Australian Oilseeds Investments, Scage Future (an EV truck company), and Capitan Investment Ltd., all of which are listed on major exchanges.

Who signed the Qualigen Therapeutics (QLGN) 8-K reporting Kevin Chen’s appointment?

The report was signed on behalf of Qualigen Therapeutics by Kevin A. Richardson II, the company’s Chief Executive Officer.

false 0001460702 0001460702 2025-09-26 2025-09-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 26, 2025

QUALIGEN THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-37428		26-3474527
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

5857 Owens Avenue, Suite 300, Carlsbad, California 92008

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code (760) 452-8111

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock (par value $0.001 per share)		QLGN		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02, Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On September 26, 2025, the Board of Directors (the “Board”) of Qualigen Therapeutics, Inc. (the “Company”) appointed Kevi Chen to serve as an independent member of the Board, effective immediately. As of the date of this Current Report on Form 8-K, Mr. Chen has not been appointed to any committees of the Board.

Kevin Chen, 47, Independent Director. Kevin Chen is currently Chief Economist and CIO of Horizon Financial. Board member of CurrenC Group (listed on Nasdaq), Australian Oilseeds Investments (listed on Nasdaq), Scage Future (EV truck company listed on Nasdaq), Capitan Investment Ltd. (listed on Toronto Stock Exchange). Former board member of Infint Acquisition Corporation (listed on the NYSE). Adjunct Associate Professor, New York University. A guest speaker at Harvard University, Fordham University, Pace University, and IESE Business School. Former member of the Adjunct Advisory Committee and former Interim Head of the Private Sector Concentration program of Ms. Global Affairs, New York University. Memeber of the Economic Club of New York. Life Member of the Council on Foreign Relations. Fellow of the Foreign Policy Association. Member of the Bretton Woods Committee. Member of the Economic Club of Miami. Editorial Advisory Board Member of the Global Commodity Applied Research Digest (GCARD) at JP Morgan Center for Commodities (JPMCC) at the University of Colorado Denver Business School. Co-Chair of the New York Finance Forum. He was Senior Portfolio Manager, Credit Agricole/Amundi Asset Management from Aug. 2008 to Oc. 2011. Director of Asset Allocation at Morgan Stanley August 2004 to August 2008. Manager at China Development Bank, September 1998 to August 2000. PhD in Finance from the Financial Asset Management Engineering Center at University of Lausanne, Switzerland at October 2004. Master’s degree in Finance, Center for Economic Research, Tilburg University in the Netherlands at August 2001. B.A. degree in Economics from the Renmin University of China in Beijing, China, July 1998.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	QUALIGEN THERAPEUTICS, INC.
Date: September 29, 2025	By:	/s/ Kevin A. Richardson II
		Kevin A. Richardson II
		Chief Executive Officer